Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
Lorenz Räber, Vice President of Swiss Society of Cardiology, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Nature Reviews Cardiology, adding:
“Intracoronary imaging in PCI: Why, when, how—and which modality? Insights from large randomized controlled trials
Our review has just been published in Nature reviews cardiology, part of Springer Nature
The publication of eight large international randomized controlled trials (each including more than 1,000 patients)—ILUMIEN IV, IVUS-ACS, IVUS-CHIP, IVUS-XPL, OCCUPI, OCTOBER, RENOVATE-COMPLEX, and ULTIMATE—has generated substantial evidence supporting the clinical use of intracoronary imaging (ICI) to improve outcomes in patients undergoing PCI.
However, heterogeneity in study populations, the lack of standardized criteria across ICI-guided PCI protocols, and mixed results across randomized trials have left important uncertainty regarding why, when, and in whom ICI guidance provides the greatest clinical benefit in daily practice.
In this 20-page review, we discuss all major randomized controlled trials of intracoronary imaging guidance—including the latest IVUS-CHIP and OPTIMAL—and provide a practical perspective on the optimal use of IVUS and OCT in contemporary PCI.
A big thanks to Flavio Biccirè (former Bern fellow, now Interventional Consultant at San Giovanni Addolorata, Rome) for his great endurance and commitment throughout this endeavour, and to all our co-author colleagues from Spain, Korea and USA who contributed to this work.
- Professor Ik-Kyung Jang from Boston Massachusetts General Hospital, Boston, USA
- Nieves Gonzalo from Hospital Clinico San Carlos, Computense de Madrid University, Madrid, Spain
- Professor Joo-Yong Hahn from Samsung Medical Center, Sungkyunkwan University, Seol, Korea
Thanks to Dr Gregory Lim for his editorial guidance.”
Title: Intracoronary imaging in percutaneous coronary intervention: why, when, how and which from large, randomized trials
Authors: Flavio Giuseppe Biccirè, Nieves Gonzalo, Joo-Yong Hahn, Ik-Kyung Jang, Lorenz Räber

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines